Specific binding sites for vasoactive intestinal polypeptide on nonadherent peripheral blood lymphocytes.
Vasoactive intestinal polypeptide (VIP), an octacosapeptide isolated from porcine duodenum and thought to have neuromodulator function in several functional systems (gastrointestinal tract, brain, lung, genital tract, heart), was recently detected in human neutrophils by radioimmunoassay. Subsequent studies demonstrated a VIP-mediated increase in lymphocyte adenylate cyclase. In this paper, VIP binding studies are presented using viable nonadherent human lymphocytes. Binding of 125I-VIP to nylon wool column-purified lymphocytes is specific, time dependent, rapid, and reversible. Bound radioactivity varies linearly with the number of cells used and is displaceable by non-iodinated VIP in a dose-dependent manner with complete displacement between 1 pM and 50 nM. Scatchard analysis of competition experiments demonstrates one class of specific binding sites with a KD of 0.47 +/- 0.23 nM and a Bmax of 24.9 +/- 7.0 pM. This Bmax represents 1700 binding sites/cell. secretin, gastric inhibitory polypeptide, and glucagon did not effectively compete with 125I-VIP for binding sites. This is the first demonstration of VIP receptors in a purified population of human lymphocytes; the data suggest that VIP may modulate lymphocyte function.
D001667:Binding, Competitive; D002448:Cell Adhesion; D002452:Cell Count; D002469:Cell Separation; D005749:Gastric Inhibitory Polypeptide / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000032:analysis*; D018005:Receptors, Vasoactive Intestinal Peptide; D012633:Secretin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000097:blood
D011956:Receptors, Cell Surface; D018005:Receptors, Vasoactive Intestinal Peptide; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D005749:Gastric Inhibitory Polypeptide; D005934:Glucagon